ralimetinib联合放化疗治疗新诊断胶质母细胞瘤的Ⅰ期试验
这项Ⅰ期试验旨在确定p38-MAPK抑制剂ralimetinib联合放疗和替莫唑胺治疗新诊断胶质母细胞瘤的最大耐受剂量。采用Tite-CRM设计进行剂量递增并扩展队列,ralimetinib每12小时口服100、200或300 mg。最大耐受剂量为100 mg/12小时,剂量限制性毒性为肝细胞溶解和皮疹。
要点
- ralimetinib联合放疗和替莫唑胺的最大耐受剂量为100 mg/12小时。
- 200 mg/12小时组3例中2例出现剂量限制性毒性:3级皮疹和3级肝细胞溶解。
- 最大耐受剂量下常见≥3级不良事件为肝细胞溶解(2/15)、皮炎/皮疹(1/15)、淋巴细胞减少(1/15)和恶心/呕吐(1/15)。
核心结论
- ralimetinib联合放疗和替莫唑胺治疗新诊断胶质母细胞瘤的最大耐受剂量为100 mg/12小时。
- 最常见的剂量限制性毒性为肝细胞溶解和皮疹。
研究设计与样本
- 开放标签剂量递增Ⅰ期试验,采用Tite-CRM设计,随后进行扩展队列。
- ralimetinib每12小时口服,每周7天,共2个周期、每周期2周,剂量为100、200或300 mg/12小时。
- 患者接受ralimetinib联合标准同期放疗(60 Gy/30次)和替莫唑胺(75 mg/m2/天),随后6周期辅助替莫唑胺(150-200 mg/m2,每28天第1-5天)。
- 共入组18例患者,其中15例接受最大耐受剂量治疗。
主要发现
- 200 mg/12小时组3例患者均出现剂量限制性毒性:1例3级面部水肿,2例3级皮疹和3级肝细胞溶解(66%)。
- 最大耐受剂量下同期放化疗期间≥3级不良事件:肝细胞溶解(2/15)、皮炎/皮疹(1/15)、淋巴细胞减少(1/15)、恶心/呕吐(1/15)。
- 未观察到替莫唑胺与ralimetinib同期给药时的相互作用。
- 在外周血单核细胞中观察到pMAPKAP-K2抑制(-54%)。
关键数值与推荐
- 最大耐受剂量:ralimetinib 100 mg/12小时联合放化疗。
- 200 mg/12小时组3例中2例(66%)出现剂量限制性毒性。
临床怎么用
- 对于新诊断胶质母细胞瘤患者,ralimetinib联合标准放化疗的推荐Ⅱ期剂量为100 mg/12小时。
- 治疗期间需监测肝细胞溶解和皮疹等剂量限制性毒性。
局限性
- 样本量小(共18例,最大耐受剂量组15例),为Ⅰ期剂量探索研究。
- 未报告疗效终点(如生存期)数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: This phase 1 trial aimed to determine the maximum tolerated dose (MTD; primary objective) of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients. MATERIALS AND METHODS: The study was designed as an open-label dose-escalation study driven by a Tite-CRM design and followed by an expansion cohort. Ralimetinib was administered orally every 12 h, 7 days a week, for 2 cycles of 2 weeks at a dose of 100, 200 or 300 mg/12 h. Patients received ralimetinib added to standard concurrent RT (60 Gy in 30 fractions) with TMZ (75 mg/m2/day) and 6 cycles of adjuvant TMZ (150-200 mg/m2 on days 1-5 every 28 days). RESULTS: The MTD of ralimetinib was 100 mg/12 h with chemoradiotherapy. The three patients treated at 200 mg/12 h presented a dose-limiting toxicity: one patient had a grade 3 face edema, and two patients had a grade 3 rash and grade 3 hepatic cytolysis (66%). Of the 18 enrolled patients, 15 received the MTD of ralimetinib. At the MTD, the grade ≥ 3 adverse events during concomitant chemoradiotherapy were hepatic cytolysis (2/15 patients), dermatitis/rash (1/15), lymphopenia (1/15) and nausea/vomiting (1/15). No interaction of TMZ and ralimetinib when administrated concomitantly has been observed. Inhibition of pMAPKAP-K2 (-54%) was observed in peripheral blood mononuclear cells. CONCLUSION: This phase 1 trial is the first trial to study the combination of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients. The MTD of ralimetinib was 100 mg/12 h. The most frequent dose-limiting toxicities were hepatic cytolysis and rash.
引用
- Biau J, Thivat E, Chautard E, et al. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma. Radiother Oncol. 2020. PMID: 32976869. doi:10.1016/j.radonc.2020.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。